Abstract
We conducted a pooled analysis of clinical trials comparing intravenous Fenoldopam
(FP) with Saline/Placebo/N-acetyl cysteine (NAC) for the prevention of contrast-induced nephropathy (CIN). Five
studies were eligible. Quantitative analyses were done with Review Manager (RevMan
version 5.2.). A total of 85 out of 353 patients in Fenoldopam group while 73 among
366 in the control group were affected due to CIN. The risk ratio for the development
of CIN in the Fenoldopam group was 1.19 compared to the control group. This was not
statistically significant. Fenoldopam is no better than Placebo/Saline or NAC in preventing
CIN, but more studies are required.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Contrast media-induced nephrotoxicity: Identification of patients at risk and algorithms for prevention.J Vasc Interv Radiol. 2001; 12: 3-9
- Intravenous contrast material-induced nephropathy: Causal or coincident phenomenon?.Radiology. 2013; 267: 106-118
- Contrast induced nephropathy after intravenous administration: Fact or fiction?.Radiol Clin North Am. 2009; 47: 789-800
- Contrast agents and renal cell apoptosis.Eur Heart J. 2008; 29: 2569-2576
- Risk scoring system for prediction of contrast-induced nephropathy in patients with preexisting renal impairment undergoing percutaneous coronary intervention.Singapore Med J. 2012; 53: 164-169
- Contrast induced nephropathy.in: ACR Manual on Contrast Media, Version 9. ACR Committee on Drugs and Contrast Media. American College of Radiology, 2013 ([Web site: http://www.acr.org/Quality-Safety/Resources/Contrast-Manual. Published 2013, Accessed: December 2013])
- Contrast-induced kidney injury: Mechanisms, risk factors and prevention.Eur Heart J. 2012; 33: 2007-2015
- Prospective randomized study of N-acetylcysteine, Fenoldopam, and Saline for prevention of radiocontrast-induced nephropathy.Catheter Cardiovasc Interv. 2002; 57: 279-283
- N-Acetylcysteine versus Fenoldopam Mesylate to prevent contrast agent-associated nephrotoxicity.J Am Coll Cardiol. 2004; 44: 762-765
- Comparison of N-acetylcysteine and Fenoldopam for preventing contrast-induced nephropathy (CAFCIN).Int J Cardiol. 2006; 109: 322-328
- Fenoldopam Mesylate for the prevention of contrast-induced nephropathy. A randomized controlled trial.J Am Med Assoc. 2003; 290: 2284-2291
- Fenoldopam mesylate blocks reduction in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy.Am Heart J. 2002; 143: 894-903
- Dopamine-1 receptor agonist: Renal effects and its potential role in the management of radiocontrast-induced nephropathy.J Clin Pharmacol. 2004; 44: 1342-1351
- Bove T, Fochi O, MajG, et al.Fenoldopam reduced the need for renal replacement therapy and in-hospital death in cardiovascular surgery: A meta-analysis, J Cardiothorac Vasc Anesth. 2008; 22: 27-33
- Preferred reporting items for systematic reviews and meta-analysis. The PRISMA statement.PLoS Med. 2009; 6: e1000097
- Meta-analysis in clinical trials.Control Clin Trials. 1986; 7: 177-188
- Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta.Am J Physiol Renal Physiol. 2012; 303: F1592-F1598
- Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role of dopamine-1 receptors.Kidney Int. 1999; 56: 206-210
- The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.Clin Pharmacol Ther. 1987; 41: 282-288
- The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.Crit Care Med. 1999; 27: 1832-1837
- Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow.J Clin Invest. 1964; 43: 1116-1124
- Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.Am J Cardiol. 2002; 89: 999-1002
- A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist Fenoldopam.Catheter Cardiovasc Interv. 2002; 55: 169-173
- Role of N-acetylcysteine to prevent contrast-induced nephropathy: A Meta-analysis.Am J Ther. 2013; ([Epub ahead of print])
- Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.PLoS One. 2013; 8: e55124
- Hemodynamic effects of an oral dopamine receptor agonist (Fenoldopam) in patients with congestive heart failure.J Am Coll Cardiol. 1985; 6: 792-796
Article info
Publication history
Published online: February 11, 2015
Accepted:
February 3,
2015
Received in revised form:
January 13,
2015
Received:
November 3,
2014
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
